Womble Bond Dickinson regulatory scientist Dr. Heather Hatcher will be a panelist for the bonus session of the Food & Drug Law Institute’s Regenerative Medicine: Regulatory, Legal, and Compliance Challenges for Cell and Gene Therapies, a virtual event to be held on June 8-9, 2021.  Heather’s section will provide an introduction to the science of cell and gene therapy. The panelists will also discuss recent therapeutic breakthroughs.
This conference will explore the latest pre-and post-market regulatory, legal, and compliance issues facing the cell and gene therapy industry. FDA and other speakers will provide updates on agency initiatives intended to expedite the development of cell and gene therapies. Speakers will also discuss issues such as standard setting for regenerative medicine terms and products; clinical development challenges; supply chain, liability, and other manufacturing issues; and FDA’s global regulatory harmonization initiative. The latest compliance and enforcement trends for regenerative therapies will also be discussed.

*This event is not hosted by Womble Bond Dickinson (US) LLP. We encourage all of our attorneys and staff to be actively involved in outside organizations as both leaders and presenters. Dr. Heather Hatcher is serving as a presenter at this event. Any registration fee for this event is set by the outside organization and not by Womble Bond Dickinson (US) LLP.

CLE points
Ohio and Virginia